New horizons in multimodality molecular imaging and novel radiotracers

Positron emission tomography (PET)/computerised tomography is now established in clinical practice for oncologic and non-oncological applications. Improvement and development of scanner hardware has allowed faster acquisitions and wider application. PET/magnetic resonance imaging offers potential improvements in diagnostic accuracy and patient acceptability but clinical applications are still being developed. A range of new radiotracers and non-radioactive contrast agents is likely to lead to a growth in hybrid molecular imaging applications that will allow better characterisation of disease processes.